Latest Manufacturing Scale News

Alexium International has acquired Microtek Laboratories’ microencapsulation and phase-change material business, backed by a $6.8 million entitlement offer to strengthen its manufacturing and innovation capabilities in the US.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

PARKD Limited has raised $1 million to fund its East Coast expansion, secured a new prefabrication facility in NSW, and landed its first pilot project with McNab Group, marking a pivotal step in its national rollout.

Alexium International Group reported a 26% rise in Q1 FY26 sales driven by new business wins and expanded foam bedding applications, while navigating tighter funding conditions.

Altech Batteries has partnered with AMPower to immediately market and distribute sodium nickel chloride batteries across Europe, Australia, and the USA, fast-tracking revenue ahead of its large-scale CERENERGY project in Germany.

DroneShield Limited has reported a remarkable turnaround in the half-year ended June 2025, posting record revenue of $72.3 million and a profit after tax of $2.1 million, reversing last year’s loss. The company also secured its largest-ever contract, signaling strong momentum in the counterdrone technology sector.

Firebird Metals has reported promising lab-scale results for its lithium manganese iron phosphate cathode material, showing a significant energy density improvement over standard LFP. The company is moving towards pilot-scale production and global commercialisation.

Vmoto Limited reported a 16% decline in total unit sales for 1Q25, offset by a strong cash position and strategic investments in e-mobility solutions and production capacity.

AML3D Limited has reported a strong December quarter marked by significant defense contract completions, a $30 million capital raise, and strategic expansion into the US and European markets. The company is poised for accelerated growth, underpinned by a major US Navy funding boost and new sector entries.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.